Abstract:Hepatocellular carcinoma (HCC) is one of the most serious malignant tumors in China and even the world, and is a global public health problem, its occurrence is insidious and has a poor prognosis. Until now, the therapeutic strategy based on doxorubicin (DOX) is not satisfactory, which may be due to their poor targeting specificity, unable to accurately identify tumor cells and tumor-like stem cells. Therefore, we aimed to established multi-strategy targeting liposomes that can improve the targeting ability and specifically recognize tumor cells and tumor-like stem cells. In this study, we prepared HCC microenvironmental targeting liposomes (PEG 5000 -PVGLIG-GA-DOX-Lip) by thin-film hydration and ammonium sulfate gradient method. Herein, the responsive peptide (PVGLIG) acts as the linker of the liposomes, and polyethylene glycol 5000 (PEG 5000 ) forms a hydration layer on the surface of the liposomes, which magnifies the enhanced permeability and retention (EPR) effect while hiding the active targeting ligand glycyrrhetinic acid (GA) and reduce the uptake of DOX by normal hepatocytes, relieve toxic side effects. When liposomes were in the microenvironment overexpression of matrix metalloproteinase (MMPs), PVGLIG-responsive peptide was specifically cleaved, PEG 5000 hydration layer was shed, and the targeting ligand GA was exposed, increasing the uptake of HCC cells and LCSCs through active targeting. Particle size of PEG 5000 -PVGLIG-GA-DOX-Lip were found to be 120.45 ± 3.58 nm with zeta potential of -(1.30 ± 0.17) mV. After incubation with MMP2, the particle size of the liposomes decreased to 107.47 ± 0.48 nm and the zeta potential was -(1.87 ± 0.06) mV. Evaluation of anti-tumor activity on HepG2 and liver cancer stem cells (LCSCs) was assessed by CCK-8 assay; IC50 values indicated around 2.2 and 1.5 folds increase in potency of PEG 5000 -PVGLIG-GA-DOX-Lip with MMP2 as compared to DOX-Lip, respectively. In addition, PEG 5000 -PVGLIG-GA-DOX-Lip with MMP2 could significantly inhibit the proliferation of HepG2 [(52.55 ± 7.42)% vs (24.26 ± 1.88)%] and LCSCs [(36.88 ± 6.64)% vs (10.98 ± 4.58)%]. Pharmacodynamic studies have shown that liposomes also have enhanced anti-HCC efficacy in vivo, which may be due to size shrinkage caused by the microenvironmental sensitivity of HCC. Thus, the unique multi-strategy targeting liposomes revealed its great potential as a promising system for the treatment of HCC. Graphical abstract Download : Download high-res image (129KB) Download : Download full-size image

In vitro targeted therapy by hepatocarcinoma-specific peptide A54

Tumor Cells-Specific Targeting Delivery Achieved by A54 Peptide Functionalized Polymeric Micelles

Combination of PHA-767491 with TRAIL Inhibits Proliferation of Hepatocellular Carcinoma Bel-7404 Cells

Specific targeting of A54 homing peptide-functionalized dextran-g-poly(lactic-co-glycolic acid) micelles to tumor cells.

Design, synthesis, and in vitro antitumor activity of a transferrin receptor‐targeted peptide–doxorubicin conjugate

A54 Peptide Modified and Redox-Responsive Glucolipid Conjugate Micelles for Intracellular Delivery of Doxorubicin in Hepatocarcinoma Therapy.

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

A Modified HLA-A*0201-restricted CTL Epitope from Human Oncoprotein (hpebp4) Induces More Efficient Antitumor Responses

Aptamer and Peptide-Modified Lipid-Based Drug Delivery Systems in Application of Combined Sequential Therapy of Hepatocellular Carcinoma

Plasmid Porf-Htrail and Doxorubicin Co-Delivery Targeting to Tumor Using Peptide-Conjugated Polyamidoamine Dendrimer

THE FURTHER CHARACTERIZATION OF THE SPECIFICALLY BINDING PEPTIDE TO HEPATOCELLULAR CARCINOMA

Targeted Delivery Of Chemotherapy Agents Using A Liver Cancer-Specific Aptamer

Recombinant lipoproteins reinforce cytotoxicity of doxorubicin to hepatocellular carcinoma.

Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway

Targeting of Hepatoma Cell and Suppression of Tumor Growth by A Novel 12mer Peptide Fused to Superantigen Tsst-1

Multifunctional SPIO/DOX-loaded A54 Homing Peptide Functionalized Dextran-g-PLGA Micelles for Tumor Therapy and MR Imaging

The Improved Delivery to Breast Cancer Based on a Novel Nanocarrier Modified with High-Affinity Peptides Discovered by Phage Display.

Visual Targeted Therapy of Hepatic Cancer Using Homing Peptide Modified Calcium Phosphate Nanoparticles Loading Doxorubicin Guided by T1 Weighted MRI

Targeted delivery of doxorubicin by SP5-52 peptide conjugated exosome nanoparticles into lung tumor: An in vitro and in vivo study

Enhanced efficacy of combined VEGFR peptide–drug conjugate and anti-PD-1 antibody in treating hepatocellular carcinoma

A multi-strategy liposome targeting hepatocellular carcinoma cells and stem cells enhances the chemotherapy effect of doxorubicin in hepatocellular carcinoma